Quality‐of‐life–adjusted survival comparison of sustained‐release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis
- 29 May 2003
- Vol. 97 (12), 3053-3060
- https://doi.org/10.1002/cncr.11449
Abstract
BACKGROUND The authors compared the quality of life of patients with solid tumor neoplastic meningitis treated in a controlled trial that compared conventional intrathecal methotrexate with a depot cytosine arabinoside liposomal injection (DepoCyt). The authors evaluated the trade‐off between toxicity and improved clinical outcome. METHODS Quality‐adjusted time without symptoms or toxicity (Q‐TWiST) analysis was used to evaluate data collected prospectively from a randomized clinical trial that compared DepoCyt with methotrexate. Sixty‐one patients with confirmed solid tumor neoplastic meningitis were randomized to receive either methotrexate or DepoCyt. RESULTS Within the 12‐month follow‐up, the average patient in the DepoCyt arm (compared with the methotrexate arm) achieved 71 more days of neurologic progression‐free survival and 52 more days of overall survival, but experienced slightly more days with toxicity. The DepoCyt regimen provided greater quality‐adjusted survival regardless of the quality‐of‐life valuations placed on time with toxicity and time following disease progression (range, 44–79 days). This gain was significant (P < 0.05) for all patients except for those who placed a high relative value on time following disease progression. CONCLUSIONS The clinical benefits of DepoCyt offset a trend toward additional toxicity among patients with sold tumor neoplastic meningitis. The magnitude of the benefit depends on how the patient values time spent in toxicity and disease progression. The results of this analysis can be used at the bedside to make evidence‐based individual treatment decisions. Cancer 2003;97:3053–60. © 2003 American Cancer Society. DOI 10.1002/cncr.11449Keywords
This publication has 19 references indexed in Scilit:
- Quality-of-Life-Adjusted Survival Analysis of High-Dose Adjuvant Interferon Alfa-2b for High-Risk Melanoma Patients Using Intergroup Clinical Trial DataJournal of Clinical Oncology, 2002
- A Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Adjuvant Radiation Therapy and Chemotherapy for Resectable Rectal CancerJNCI Journal of the National Cancer Institute, 1996
- Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survivalThe Lancet, 1996
- A quality‐adjusted survival meta‐analysis of adjuvant chemotherapy for premenopausal breast cancerStatistics in Medicine, 1995
- Comparing Treatments Using Quality-Adjusted Survival: The Q-Twist MethodThe American Statistician, 1995
- Evaluation of the Quality of Life Associated with Zidovudine Treatment in Asymptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1994
- Quality-of-Life Evaluation in a Clinical Trial of Zidovudine Therapy in Patients with Mildly Symptomatic HIV InfectionAnnals of Internal Medicine, 1992
- Quality-of-Life-Adjusted Evaluation of Adjuvant Therapies for Operable Breast CancerAnnals of Internal Medicine, 1991
- Quality adjusted survival analysisStatistics in Medicine, 1990
- Leptomeningeal cancer in leukemia and solid tumorsCurrent Problems in Cancer, 1988